

CORPORATE FACT SHEET




Corporate Profile:

IntriCon Corporation (NASDAQ: IIN), a medical device company based in Arden Hills, MN, is committed to enhancing the mobility and effectiveness of body-worn devices that connect people to people and to devices around them. IntriCon serves the body-worn device market by designing, developing, engineering, distributing, and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for medical bio-telemetry devices, value hearing health, professional audio communication devices. Over the past several years, IntriCon has increased investments in the continued development of four critical core technologies: Ultra-Low-Power Digital Signal Processing, Ultra-Low-Power Wireless, Microminiaturization, and Miniature Transducers. These four core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable more advanced devices. IntriCon is focused on three key markets: medical, value based hearing healthcare, and professional audio communications. Utilizing this expertise IntriCon is moving to: improve margins by actively increasing the percentage of proprietary content; increase core business revenue and margins by maximizing product research and development; strengthen its leadership position in the body-worn device market by pursuing merger and acquisition opportunities. More information about the company and its products can be found at www.intricon.com.

Revenue & EPS (continuing operation) Quarterly Trends



TTM Revenue by Market from continuing operations




Stock Performance:

IIN (Common Stock)	
Exchange	NASDAQ GM (US Dollar)
Price	\$56.20
Volume Change	-13%
Volume	336,700
52 Week Range	\$10.40 - \$76.80
Market Cap	\$485,576
EPS from Continuing Rolling Operations	\$0.58
PE Ratio	97
Shares Outstanding	8,640,143

Data as of 09/30/2018

For more up-to-date stock performance information, visit the Investor Relations section on www.IntriCon.com.



INVESTOR CONTACT: SCOTT LONGVAL

Chief Financial Officer, Secretary & Treasurer
 Phone 651-604-9526
slongval@IntriCon.com



Recent Events:

August 20, 2018

The Company completed a public offering of 1,725,000 shares of its common stock. All shares in the offering were sold by the Company at a price to the public of \$55.00 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, and board and management stock repurchases, totaled more than \$63.0 million. The company used a portion of these proceeds to pay off bank debt and invested the remainder in short-term investment securities.

Financial Update:

November 5, 2018

For the 2018 third quarter, the company reported net sales of \$30.1 million, up 20.2 percent from \$25.1 million in the prior-year period. The increase was primarily due to year-over-year revenue gains from IntriCon's largest medical customer and growth in its value-based hearing healthcare business. IntriCon posted net income attributable to shareholders of \$1.9 million, or \$0.22 per diluted share, versus \$1.3 million or \$0.17 per share, for the 2017 third quarter. Concluded Gorder, "We believe we are in the early stages of long-term, sustained growth within our core markets. The diabetes market is experiencing tremendous growth, with CGM being a critical component to serving the needs of many diabetics. The value-hearing healthcare space is just beginning to emerge, and we are at the forefront of providing affordable and accessible solutions to unserved or underserved hearing-impaired Americans. In addition, we believe the forthcoming regulatory changes will provide further tailwinds. Looking ahead, given our competitive advantages, numerous opportunities for growth and strong financial position, we are extremely well-positioned for continued success."

Corporate Governance:

Mark S. Gorder	President, CEO & Founder
J. Scott Longval	CFO, Secretary & Treasurer
Mike Geraci	VP, Sales & Marketing
Dennis Gonsior	VP, Global Operations
Greg Gruenhagen	VP, Quality & Regulatory Affairs

Corporate Headquarters:

IntriCon Corporation	Tel: 651.636.9770
1260 Red Fox Road	Fax: 651.636.9503
Arden Hills, MN 55112	www.IntriCon.com